DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $152,582 | -4.1% | 615 | -7.2% | 0.04% | -9.1% |
Q2 2023 | $159,130 | +32.3% | 663 | +38.7% | 0.04% | +29.4% |
Q1 2023 | $120,322 | -33.5% | 478 | -28.0% | 0.03% | -33.3% |
Q4 2022 | $180,830 | -6.3% | 664 | -10.3% | 0.05% | -19.0% |
Q3 2022 | $193,000 | -1.0% | 740 | +10.6% | 0.06% | +8.6% |
Q2 2022 | $195,000 | -14.8% | 669 | -14.3% | 0.06% | -7.9% |
Q1 2022 | $229,000 | -23.7% | 781 | -14.4% | 0.06% | -30.0% |
Q4 2021 | $300,000 | +19.5% | 912 | +10.5% | 0.09% | +1.1% |
Q3 2021 | $251,000 | +56.9% | 825 | +38.4% | 0.09% | +53.4% |
Q2 2021 | $160,000 | -7.0% | 596 | -22.2% | 0.06% | -15.9% |
Q1 2021 | $172,000 | -8.0% | 766 | -8.8% | 0.07% | -24.2% |
Q4 2020 | $187,000 | +152.7% | 840 | +143.5% | 0.09% | +127.5% |
Q3 2020 | $74,000 | +131.2% | 345 | +90.6% | 0.04% | +122.2% |
Q2 2020 | $32,000 | +39.1% | 181 | +7.7% | 0.02% | +38.5% |
Q1 2020 | $23,000 | -11.5% | 168 | 0.0% | 0.01% | +8.3% |
Q4 2019 | $26,000 | – | 168 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |